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Drug delivery in biological tissues:
a two-layer reaction-diffusion-convection model
Sean McGinty and Giuseppe Pontrelli
Abstract In this paper we present a general model of drug release from a drug
delivery device and the subsequent drug transport in biological tissue. In order to
study the complete process, a two-phase mathematical model describing the trans-
port of a drug between two coupled media of different properties and dimensions is
presented. A system of partial differential equations describes both the solid-liquid
transfer and diffusion processes in the polymeric substrate as well as diffusion, con-
vection and reaction in the tissue layer. The model serves as a useful tool for pro-
viding insight into the concurrent effects of the diffusion, convection, solid-liquid
transfer and reaction parameters in drug delivery systems.
1 Introduction
Local drug delivery devices (DDD) have received much attention in recent years,
since they provide a convenientmeans of targeting drug at the site where it is needed
most. Historically, drugs have been administered either orally, topically or hypoder-
mically, and often by the patients themselves. The advent of local DDD has meant
that drug delivery can be more controlled, with a prescribed amount of drug be-
ing delivered over the necessary time period, and with less input required from the
patient. Whilst the drug delivery may in principle be monitored, it is often unclear
how the DDD can be designed to achieve the level of control required for a specific
purpose, since there exists complex interplay between biology, polymer chemistry
and pharmacology [1].
Important examples of local DDD include drug-eluting stents for the prevention
of restenosis following percutaneous coronary intervention [2], therapeutic contact
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Fig. 1 Three examples of DDD: the drug-eluting stent (left), the transdermal patch (center), the
therapeutic contact lens (right).
lenses to deliver ophthalmic drugs [3], and transdermal drug delivery [4] (Fig. 1).
In each case, the drug is commonly contained in a polymeric gel platform that is
in direct contact with the biological tissue. The polymeric gel acts as a reservoir
of drug and provides an adjustable level of control over the rate of drug delivery
to the tissue [5]. Both the polymeric gel layer and the interfaced tissue are treated
as porous media from a macroscopic point of view. The therapeutic success is de-
pendent on the extent of drug elution, the rate of release, accumulation of drug and
binding to components within the tissue [6]. Furthermore, the local drug concentra-
tions achieved are directly correlated with biological effect and local toxicity. The
pharmacological effects of the drug, tissue accumulation, duration and distribution
could potentially have an effect on its efficacy and a delicate balance between ade-
quate amount of drug delivered over an extended period of time and minimal local
toxicity should be found [7].
Mathematical modelling can serve as an extremely useful tool for providing
insight into the important parameters in the system, and to give an indication of
how the device may be modified to achieve the desired drug release profile. Many
studies on DDD have been conducted regarding efficacy and optimal design either
with experimental methods, or modelling/numerical simulations, or a combination
of both [8–11]. Nonetheless, many questions remain unanswered for bioengineers
and pharmaceutics developers who continue to explore and evaluate this technology.
In particular, finding the optimum dose to be delivered in a personalized way to a
specific tissue still remains a significant challenge.
In this paper we present a general mathematical model of drug release from a
DDD and the subsequent drug transport in a biological tissue. In order to study the
complete process, a two-phase mathematical model describing the dynamics of a
drug between two coupled media of different properties and dimensions is proposed.
A system of partial differential equations describes both the solid-liquid transfer and
diffusion processes in the polymer as well as diffusion, convection and reaction in
the tissue layer.
Drug delivery in biological tissues 3
2 Formulation of the problem
In a typical DDD, the mass dynamics occurs across a two-layered system composed
of: (i) a polymeric platform, acting as a reservoir, where the drug is initially con-
tained, and (ii) the biological tissue (the release medium) where the drug is directed,
and exerts a therapeutical effect (Fig. 2).
Layer (i) is shaped as a planar slab, enclosed on one side with an impermeable
backing and having the other side in contact with layer (ii). A rate-controlling mem-
brane protecting the polymer matrix may exist at the interface (i)-(ii). It is important
to emphasize here that the drug dynamics intrinsically depends on the properties of
the coupled system. As most of the mass dynamics occurs along the direction nor-
mal to the tissue surface, the modelling may reasonably be restricted to a simplified
one-dimensional case. In particular, we consider the x-axis to be normal to the layer
surface and oriented with the positive direction outwards.Without loss of generality,
let x0 = 0 be the interface and let l0 and l1 be the thicknesses of the layers (i) and (ii)
respectively, with l1 ≫ l0 (Fig. 2). The layers are both treated from a macroscopic
perspective so that they are represented as two homogeneous porous media.
Preliminary definitions and nomenclature
In the continuum approach, a porous medium can be represented as a homogeneous
material by defining averaged variables over a large enough volume, the represen-
tative elementary volume (r.e.v.)Vrev , of size larger than the pore scale, but smaller
than the typical length scale of the phenomenon. Let us define porosity, ε , as the
ratio of void volume (V
f
rev) to total volume (Vrev =V
f
rev +V
s
rev). It may be that not all
void space is accessible to solute. For example, the pore size may be smaller than
the size of the solute molecules, or some of the voids may be isolated and not con-
nected to other pores. Thus we introduce a new parameter, the partition coefficient
(k), such that kε represents the available void volume. We indicate by φ the ratio of
accessible void volume to solid volume:
Fig. 2 Cross section of a typical DDD, showing the schematic drug delivery mechanism between
polymer and tissue, the geometrical configuration and the reference system. Due to an initial dif-
ference of free drug concentrations c0 and c1, a mass flux is established at the interface and drug
diffuses through the biological tissue. Figure not to scale.
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φ =
kε
1− ε
. (1)
When defining the concentration, two different ways of averaging over a volume
exist. One is based on the volume of each phase contained in r.e.v., that is kV
f
rev,
for the accessible fluid-phase1(which is the fraction kε of the r.e.v.) and V srev for the
solid-phase (which is the fraction 1− ε of the r.e.v.). Another way is to average
over the whole Vrev =V
f
rev +V srev [12]. In the first case, we refer to intrinsic volume-
averaged drug concentration in accessible fluid and solid phases c f and cs (µg/ml),
in the second, to volume-averaged drug concentrations, c and c∗. They are related
by the relationships:
c = kεc f , c∗ = (1− ε)cs. (2)
3 Modelling drug dynamics in the polymer (delivery)
Initially, the drug exists wholly in a solid phase encapsulated within the polymer
matrix (e.g. nanoparticles or crystalline form)(cs0): in such a state, it is unable to be
delivered to the tissue. When exposed to biological fluid, as in the in-vivo case, the
polymer becomes wetted, initiating a solid-liquid mass transfer (dissolution) pro-
cess, providing a means for the drug to elute from the device. The rate of transfer of
drug from the solid phase to the biologically available free phase (c
f
0) is proportional
to the difference between cs0 and c
f
0 . Since the diffusion of drug in the solid phase is
negligible, it can be shown that the equations for the drug dynamics in layer (i) in
terms of volume averaged concentrations (2) are:
∂c∗0
∂ t
=−α0 (φ0c
∗
0− c0) in (−l0,0) (3)
∂c0
∂ t
= D0
∂ 2c0
∂x2
+α0 (φ0c
∗
0− c0) in (−l0,0) (4)
where D0 (cm
2 · s−1) is the effective diffusion coefficient of the solute and the solid-
liquid rate parameter α0(s
−1) incorporates a mass transfer coefficient and the hy-
draulic radius (free flow area over wetted perimeter) [12].
4 Modelling drug dynamics in the tissue (absorption)
Following the solid-liquid transfer process, the now biologically available drug dif-
fuses through the polymeric layer and crosses the interface into the biological tissue.
1 Superscripts s and f denote solid and fluid phases, respectively. Subscripts 0 and 1 indicate layers
(i) and (ii) respectively.
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This is typically comprised of several layers of different size and composition, but
for the purposes of this paper we consider tissue as a homogeneous single-layered
medium. However, the model may be extended to multi-layers following the ap-
proach of [13]. Within the release medium the free drug undergoes diffusion and,
in many cases, convection due to a pressure difference across the tissue. In addi-
tion, the drug may bind reversibly to specific components of the tissue: indeed, the
drug is often targeted to bind to specific receptors on the surface of or within cells.
These binding/unbinding processes are often referred to as association/dissociation.
We model the binding/unbinding process as a first order reaction, similarly to the
liquid/solid mass transfer in (3)–(4). However, in contrast to layer (i), we account
for different rates between the forward and reverse reactions, say β1 and δ1 ≥ 0
(s−1) which, here, are defined as the inverse of the forward and reverse reaction
time scales, respectively. They are related through the equilibrium dissociation con-
stant, K1 =
δ1
β1
, a parameter which can typically be measured experimentally [14].
Here we denote the free and bound drug concentrations as c
f
1 and c
s
1 respectively.
Thus, in the biological tissue, the two-phase drug dynamics is governed by the linear
reaction-convection-diffusionequations in terms of volume averaged concentrations
(2):
∂c1
∂ t
= D1
∂ 2c1
∂x2
− v
∂c1
∂x
− δ1
(
c1
K1
−φ1c
∗
1
)
in (0, l1) (5)
∂c∗1
∂ t
= δ1
(
c1
K1
−φ1c
∗
1
)
in (0, l1) (6)
where D1 is the effective diffusivity of unbound drug and v (cm · s
−1) is the magni-
tude of the convection which is assumed to act in the positive x direction. We have
made the assumption that the drug does not diffuse within the components to which
it is bound.
We note that the first order linear reaction model of the binding/unbinding pro-
cess in (5)–(6) may not be the most suitable in all circumstances. In some appli-
cations of DDD, such as in drug-eluting stents, a second-order saturable reversible
binding model has been proposed to describe the binding of limus compound drugs
to arterial tissue [6]: this comprehensivemodel includes a number of drug dependent
parameters which are difficult to measure experimentally and, nevertheless, does not
necessarily apply in all DDD. Even in cases where a non-linear model is generally
more appropriate, the linear model with suitably chosen parameter values can be
shown to suffice in certain circumstances (i.e at early times and for sufficiently high
initial drug concentrations and binding site density).
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5 Boundary, interface and initial conditions
To close the previous two-layer mass transfer system of eqns. (3)–(6), a flux conti-
nuity condition has to be assigned at the layer (i)–(ii) interface:
−D0
∂c0
∂x
=−D1
∂c1
∂x
+ vc1 at x = 0.
As far as the concentration continuity is concerned, this is not guaranteed because
of a different drug partitioning between the two layers [13]. Additionally, a semi-
permeable rate-controlling membrane or a non-perfect contact, having 1/P as mass
resistance, might be present at the interface. Thus, a jump concentration may occur:
−D1
∂c1
∂x
= P
(
c0
k0ε0
−
c1
k1ε1
)
at x = 0,
with P(cm · s−1) the overall mass transfer coefficient [13].
No mass flux passes to the outer surrounding due to the impermeable backing
and we impose a no-flux condition :
D0
∂c0
∂x
= 0 at x =−l0.
Finally, a boundary condition has to be imposed at the external boundary. De-
pending on the thickness of the tissue, the concentration may vanish at this point.
However, we propose the more general Robin boundary condition (from which
c1 = 0 can be recovered by choosing γ sufficiently large):
−D1
∂c1
∂x
+ vc1 = γc1 at x = l1.
The initial conditions are:
c∗0(x,0) =Ce c0(x,0) = 0 c1(x,0) = 0 c
∗
1(x,0) = 0.
6 Model solution
The model we have presented is very general and may be applied to several
DDD. It is often useful to write a model in non-dimensional form. A typical non-
dimensionalization for a system of reaction-diffusion-convection equations leads to
three important numbers: the Pe´clet number, the first Damko¨hler number and the
second Damko¨hler number. These dimensionless groups define, respectively, the
relative importance of convection to diffusion, of reaction to convection, and of
reaction to diffusion. By examining their size, it is often possible to simplify the
model by neglecting parameters that are unimportant. For example, in the case of
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drug-eluting stents, while there exists a small convective flow due to the transmural
pressure gradient across the arterial wall, the Pe´clet number is often small, meaning
that the convective term can be reasonably neglected. Depending on the particular
DDD, it may also be possible to neglect the solid-liquid mass transfer terms if the
timescale for this process is far shorter than that of diffusion in the polymer. Simi-
larly, if the timescale for reaction is far shorter than that of diffusion and convection,
then the reaction may be considered instantaneous, in which case the two phases in
the tissue can be assumed to be in dynamic equilibrium. When the model has been
simplified as far as can be, an analytical or semi-analytical solution may be obtained
by using the techniques described in [13,15,16], or alternatively, an appropriate nu-
merical procedure can be used.
7 Summary
In this paper we have presented a general model of drug release from a DDD and
the subsequent drug transport in biological tissue. The model is based on a two-
layer two-phase system where a system of partial differential equations describes
both the solid-liquid transfer and diffusion processes in the polymeric layer as well
as diffusion, convection and reaction in the tissue layer. We have indicated how
the model may be tuned and simplified to suit the required application and have
suggested suitable solution techniques.
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